Wilson Eleanor M, Rosenthal Elana S, Kattakuzhy Sarah, Tang Lydia, Kottilil Shyam
Institute of Human Virology, University of Maryland School of Medicine, University of Maryland, Baltimore, Maryland, USA.
Critical Care Medicine Department of the NIH Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Clin Microbiol Rev. 2017 Jan;30(1):23-42. doi: 10.1128/CMR.00037-16. Epub 2016 Oct 19.
Directly acting antiviral (DAA) combination therapies for chronic hepatitis C virus (HCV) infection are highly effective, but treatment decisions remain complex. Laboratory testing is important to evaluate a range of viral, host, and pharmacological factors when considering HCV treatment, and patients must be monitored during and after therapy for safety and to assess the viral response. In this review, we discuss the laboratory tests relevant for the treatment of HCV infection in the era of DAA therapy, grouped according to viral and host factors.
用于慢性丙型肝炎病毒（HCV）感染的直接作用抗病毒（DAA）联合疗法非常有效，但治疗决策仍然复杂。在考虑HCV治疗时，实验室检测对于评估一系列病毒、宿主和药理学因素很重要，并且在治疗期间和治疗后必须对患者进行监测，以确保安全并评估病毒反应。在本综述中，我们将根据病毒和宿主因素对DAA治疗时代与HCV感染治疗相关的实验室检测进行讨论。
